Insider Trading November 11, 2026 09:46 PM

Cooper Companies Director Kurzius Buys $549,320 in Stock at a Discount

The open-market purchase of 10,000 shares comes as the company faces guidance cuts and mixed analyst views.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
COO

Lawrence Erik Kurzius, a director at The Cooper Companies, Inc. (NYSE:COO), acquired 10,000 shares of common stock on September 16, 2026, for a total of $549,320, at an average price of $54.932 per share. The purchase price represents a significant discount to the current stock price of $62.93. Following the transaction, Kurzius directly holds 31,099 shares. The insider buy coincides with a period of heightened scrutiny for Cooper Companies, which recently reported third-quarter fiscal 2026 revenue below expectations, lowered its financial guidance for the remainder of fiscal 2026, and received a downgrade from William Blair to Market Perform from Outperform. Other analysts have also adjusted their views: Mizuho cut its price target to $75 from $85, Stifel maintained a Buy rating with a $70 target, Piper Sandler reiterated Neutral with a $59 target, and Needham lowered its target to $73 from $86 while keeping a Buy rating. The stock trades at a P/E ratio of 21.71 and a PEG ratio of 0.49, and management has been aggressively buying back shares.

Cooper Companies Director Kurzius Buys $549,320 in Stock at a Discount
COO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Lawrence Erik Kurzius bought 10,000 shares at $54.932 per share, a significant discount to the current price of $62.93, increasing his direct holdings to 31,099 shares.
  • The purchase occurs as Cooper Companies faces a revenue miss in Q3 fiscal 2026, lowered guidance, and a downgrade by William Blair, with analysts adjusting price targets.
  • The stock’s valuation metrics (P/E of 21.71 and PEG of 0.49) and management’s share buyback activity are highlighted alongside the insider transaction.

Lawrence Erik Kurzius, a director at The Cooper Companies, Inc. (NYSE:COO), purchased 10,000 shares of the company’s common stock on September 16, 2026, according to a recent disclosure. The transaction was valued at $549,320, with the shares acquired at a price of $54.932 per share.

The purchase price stands at a notable discount to the current market price of $62.93, implying that the director acquired the stock well below recent trading levels. Following the acquisition, Kurzius directly holds 31,099 shares of Cooper Companies common stock.

The insider buy comes at a time when Cooper Companies has drawn increased attention from investors and analysts. The company’s third-quarter fiscal 2026 revenue fell short of expectations, although earnings per share aligned with consensus estimates after accounting for tariff refunds. Management subsequently lowered its financial guidance for the remainder of fiscal 2026.

Analyst reactions have been mixed. William Blair downgraded Cooper Companies to Market Perform from Outperform following an earnings miss attributed to inventory destocking and the decision not to sell the CooperSurgical division after a strategic review. Mizuho adjusted its price target downward to $75 from $85, citing softness in CooperVision sales growth and a weak outlook for the first half of fiscal year 2027. Stifel maintained a Buy rating with a $70 price target, predicting growth for CooperVision in fiscal year 2027, albeit below consensus estimates. Piper Sandler reiterated a Neutral rating with a $59 price target, addressing potential strategic and governance changes within the company. Needham also lowered its price target to $73 from $86 but kept a Buy rating on the shares.

On the valuation front, Cooper Companies appears undervalued based on a Fair Value assessment, with the stock trading at a P/E ratio of 21.71 and a PEG ratio of 0.49. This insider purchase aligns with a noted tip that management has been aggressively buying back shares.

The transaction adds to the mix of signals investors are weighing as they assess the company’s outlook amid recent operational and strategic developments.

Risks

  • Continued softness in CooperVision sales growth and a weak outlook for the first half of fiscal 2027 could pressure the stock further, as noted by Mizuho’s price target cut.
  • The decision not to sell the CooperSurgical division after a strategic review may leave strategic and governance questions unresolved, as referenced by Piper Sandler’s Neutral rating.
  • Inventory destocking and the earnings miss that led to William Blair’s downgrade could signal ongoing operational challenges.

More from Insider Trading

Ambiq Micro CTO Offloads $421,942 in Stock as Shares Extend Rally Nov 11, 2026 QuantumScape CTO Offloads $610,524 in Shares as Stock Hovers Near 52-Week Low Nov 11, 2026 Core Scientific Director Eric Weiss Buys $97,979 in Shares as Stock Trades Below Purchase Price Nov 11, 2026 Workday Director David Duffield Offloads $18.6 Million in Stock Under Prearranged Plan Nov 11, 2026 Ciena CEO Offloads Nearly $1 Million in Stock Under Pre-Set Trading Plan Nov 11, 2026